Literature DB >> 10356109

Primary hypoxic tolerance and chemical preconditioning during estrus cycle in mice.

K Kasischke1, R Huber, H Li, M Timmler, M W Riepe.   

Abstract

BACKGROUND AND
PURPOSE: Exogenous application of estrogens or progesterone ameliorates hypoxic/ischemic cell damage. This study investigates whether values of primary and induced hypoxic tolerance vary endogenously during the estrus cycle in female mice.
METHODS: Population spike amplitude (PSA) and NADH were measured during hypoxic hypoxia and recovery in hippocampal slices from untreated control animals (C slices) and slices prepared from animals pretreated in vivo with a single intraperitoneal injection of 3-nitropropionate (3NP) (3NP slices) or acetylsalicylate (ASA) (ASA slices).
RESULTS: Posthypoxic recovery of PSA was dose dependent in 3NP slices from males, with maximal recovery on pretreatment attained with 20 mg/kg 3NP (82+/-32% [mean+/-SD]; C slices, 38+/-29%; P<0.01). PSA recovered to 17+/-12% in C slices during proestrus, 43+/-23% during estrus, and 63+/-44% during diestrus. In 3NP slices, recovery of PSA increased to 57+/-36% (P<0. 05) during proestrus. Hypoxic tolerance was not increased in other stages of the estrus cycle. Hypoxic NADH increase during proestrus declined from 212+/-76% in C slices to 133+/-11% in 3NP slices (P<0. 05). Recovery of PSA in ASA slices was 75+/-36% (P<0.01 versus control) in males and 48+/-34% during proestrus (P<0.05 versus ASA slices from males).
CONCLUSIONS: Primary and induced hypoxic tolerance are endogenously modulated during the estrus cycle. Differences in hypoxic oxidative energy metabolism mediate part of the differential tolerance. Experimental and clinical therapeutic strategies against cerebral ischemia/hypoxia need to consider sex-related dependence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356109     DOI: 10.1161/01.str.30.6.1256

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Pharmacologic preconditioning: translating the promise.

Authors:  Jeffrey M Gidday
Journal:  Transl Stroke Res       Date:  2010-01-03       Impact factor: 6.829

2.  Is there a place for cerebral preconditioning in the clinic?

Authors:  Richard F Keep; Michael M Wang; Jianming Xiang; Ya Hua; Guohua Xi
Journal:  Transl Stroke Res       Date:  2010-01-14       Impact factor: 6.829

3.  Gender-specific response to isoflurane preconditioning in focal cerebral ischemia.

Authors:  Hideto Kitano; Jennifer M Young; Jian Cheng; Lan Wang; Patricia D Hurn; Stephanie J Murphy
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-31       Impact factor: 6.200

4.  Gender- and region-specific expression of insulin receptor protein in mouse brain: effect of mild inhibition of oxidative phosphorylation.

Authors:  W H Xu; R Huber; M W Riepe
Journal:  J Neural Transm (Vienna)       Date:  2006-11-06       Impact factor: 3.575

Review 5.  Inhalational anesthetics as preconditioning agents in ischemic brain.

Authors:  Lan Wang; Richard J Traystman; Stephanie J Murphy
Journal:  Curr Opin Pharmacol       Date:  2007-10-24       Impact factor: 5.547

Review 6.  Secondary stroke prevention: inside the vessels and beyond.

Authors:  Matthias W Riepe; Roman Huber
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.